相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2023)
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
Alice B. Gottlieb et al.
ACTA DERMATO-VENEREOLOGICA (2022)
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Brigitte Michelsen et al.
ARTHRITIS CARE & RESEARCH (2022)
Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study
Alicia Garcia-Dorta et al.
FRONTIERS IN MEDICINE (2022)
Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
Manuel Jose Moreno-Ramos et al.
RHEUMATOLOGY AND THERAPY (2022)
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
Sara Alonso et al.
FRONTIERS IN MEDICINE (2021)
Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
Jurgen Braun et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2021)
Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS)
Xenofon Baraliakos et al.
CLINICAL DRUG INVESTIGATION (2020)
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
Uta Kiltz et al.
ADVANCES IN THERAPY (2020)
One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study
Maria Sole Chimenti et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
Stefano Gentileschi et al.
MEDIATORS OF INFLAMMATION (2020)
Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
Denis Poddubnyy et al.
BMJ OPEN (2020)
HOW DO TNF-ALPHA-INHIBITORS IN MEDICAL HISTORY AFFECT PATIENT REPORTED OUTCOMES AND RETENTION IN ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH SECUKINUMAB IN REAL WORLD? - GERMAN AQUILA STUDY
U. Kiltz et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study
Karel Pavelka et al.
ACR OPEN RHEUMATOLOGY (2020)
Comorbidity burden in axial spondyloarthritis: a cluster analysis
Sizheng Steven Zhao et al.
RHEUMATOLOGY (2019)
SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM
Atul Deodhar et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
REAL-WORLD EXPERIENCE OF SECUKINUMAB FOR AXIAL SPONDYLOARTHRITIS: SPECIFIC POPULATION CHARACTERISTICS
Valentina Emperiale et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A. Deodhar et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis
Clementina Lopez-Medina et al.
RMD OPEN (2019)
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
Xenofon Baraliakos et al.
RMD OPEN (2019)
Radiographic progression in non-radiographic axial spondyloarthritis
Mikhail Protopopov et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study
Alan J. Kivitz et al.
RHEUMATOLOGY AND THERAPY (2018)
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
Juergen Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Patient Burden of Axial Spondyloarthritis
Vibeke Strand et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2017)
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
H. Marzo-Ortega et al.
ARTHRITIS CARE & RESEARCH (2017)
Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
Helena Marzo-Ortega et al.
RMD OPEN (2017)
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
Karel Pavelka et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Anti-IL17A in Axial Spondyloarthritis-Where Are We At?
Peter P. Cheung
FRONTIERS IN MEDICINE (2017)
Which aspects of health are most important for patients with spondyloarthritis? A Best Worst Scaling based on the ASAS Health Index
Uta Kiltz et al.
RHEUMATOLOGY (2016)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Axial spondyloarthritis
Joachim Sieper et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?
X. Baraliakos et al.
RMD OPEN (2015)
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
M. Rudwaleit et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
分享论文
